The role of neoadjuvant chemotherapy in patients with primary resectable pancreatic cancer: A retrospective cohort study
- 作者: Khatkov I.1, Semenov N.1, Izrailov R.1, Efanov M.1, Dalgatov K.2,3, Zhukova L.1
-
隶属关系:
- Loginov Moscow Clinical Scientific Center
- Research Institute of Clinical Surgery of Pirogov Russian National Research Medical University
- Pirigov City Clinical Hospital №1
- 期: 卷 25, 编号 2 (2023)
- 页面: 236-240
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132823
- DOI: https://doi.org/10.26442/18151434.2023.2.202295
- ID: 132823
如何引用文章
全文:
详细
Background. Currently available data on the efficacy and indications for neoadjuvant chemotherapy in patients with primary resectable pancreatic cancer are contradictory and not clearly defined.
Aim. To conduct a comparative assessment of the effectiveness of neoadjuvant chemotherapy and primary surgical treatment followed by adjuvant chemotherapy in patients with primary resectable pancreatic cancer.
Materials and methods. In our study, the efficacy of neoadjuvant chemotherapy was retrospectively evaluated in 45 patients and in 153 patients with primary surgical treatment and subsequent adjuvant chemotherapy.
Results. With a median follow-up of 41.7 months. Both, recurrence free survival in the group of patients receiving neoadjuvant chemotherapy followed by surgical treatment (n=33; 73%) and in the group with surgical treatment and subsequent adjuvant chemotherapy (13.9 and 19.5 months; p=0.35) and overall survival (28.4 months vs 33.7 months; p=0.29) were no different. The CA level of 19.9>500 IU/ml in the neoadjuvant chemotherapy group was observed in 20 (44.4%) patients. At the same time, surgical treatment was performed only in 11 (55%) patients. At the same time, at the CA 19.9 level <500 IU/ml, at the end of neoadjuvant chemotherapy, surgical treatment was not performed in only 3 (12%) patients (p=0.005).
Conclusion. The long-term results of treatment of patients with primary resectable pancreatic cancer, whose first stage was neoadjuvant chemotherapy, practically do not differ from the group whose treatment began with surgery. Treatment of patients with an initially high (>500 IU/ml) level of CA 19.9 is preferable to start with neoadjuvant chemotherapy. Patients who may have doubts about the likelihood of adjuvant chemotherapy (general condition, social adaptation, place of residence), it is also preferable to start treatment with neoadjuvant chemotherapy. It is necessary to change the algorithm of examination of patients, especially those with a level of CA 19.9>500 IU/ml, to exclude a greater prevalence, for example, performing diagnostic laparoscopy to exclude metastases in the peritoneum.
作者简介
Igor Khatkov
Loginov Moscow Clinical Scientific Center
Email: i.hatkov@mknc.ru
ORCID iD: 0000-0002-4088-8118
D. Sci. (Med.), Prof., Acad. RAS
俄罗斯联邦, MoscowNikolai Semenov
Loginov Moscow Clinical Scientific Center
Email: nn.semenov@mknc.ru
ORCID iD: 0000-0003-4691-7490
SPIN 代码: 8696-2556
D. Sci. (Med.)
俄罗斯联邦, MoscowRoman Izrailov
Loginov Moscow Clinical Scientific Center
Email: r.izrailov@mknc.ru
ORCID iD: 0000-0002-1935-869X
D. Sci. (Med.)
俄罗斯联邦, MoscowMikhail Efanov
Loginov Moscow Clinical Scientific Center
Email: m.efanov@mknc.ru
ORCID iD: 0000-0003-0738-7642
D. Sci. (Med.)
俄罗斯联邦, MoscowKamil Dalgatov
Research Institute of Clinical Surgery of Pirogov Russian National Research Medical University; Pirigov City Clinical Hospital №1
编辑信件的主要联系方式.
Email: kkd1111@mail.ru
ORCID iD: 0000-0001-5324-4752
Cand. Sci. (Med.), Senior Res. Officer
俄罗斯联邦, Moscow; MoscowLiudmila Zhukova
Loginov Moscow Clinical Scientific Center
Email: kkd1111@mail.ru
ORCID iD: 0000-0003-4848-6938
D. Sci. (Med.), Corr. Memb. RAS
俄罗斯联邦, Moscow参考
- Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088-96.
- Ahmad SA, Duong M, Sohal DPS, et al. Surgical Outcome Results from SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020;272(3):481-6. doi: 10.1097/SLA.0000000000004155
- Ettrich TJ, Uhl W, Kornmann M, et al. Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial. J Clin Oncol. 2022;40(suppl. 16):abstr 4133.
- Al-Batran SE, Reichart A, Bankstah US, et al. Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. J Clin Oncol. 2021;39(suppl. 3):abstr 406.
- Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763-73. doi: 10.1200/JCO.19.02274
- Unno M, Motoi F, Matsuyama Y, et al. Randomized Phase II/III Trial of Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer (Prep-02/JSAP-05). J Clin Oncol. 2019;37(4_suppl):189. doi: 10.1200/JCO.2019.37.4_suppl.189
- Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant Chemoradiation Therapy With Gemcitabine/Cisplatin and Surgery Versus Immediate Surgery in Resectable Pancreatic Cancer: Results of the First Prospective Randomized Phase II Trial. Strahlenther Onkol. 2015;191(1):7-16. doi: 10.1007/s00066-014-0737-7
- Isaji Sh, Mizuno Sh, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11. doi: 10.1016/j.pan.2017.11.011
- Tsai S. Who Goes First? The Optimal Timing of Surgical Intervention in Operable Pancreas Cancer. 2020 ASCO Virtual Scientific Program. Session Type: Oral Abstract Session.